TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19155032

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Blood draw visits (6 weeks and 6 months)
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Community engagement strategies (monitoring losses, allowing mothers to witness blood draw, community meetings)
Number of subjects: 1085
Study: 16442641

Group type: EXPERIMENTAL
Intervention: Updating condition (visual stimulus shown before saccade)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition (no visual stimulation before saccade)
Number of subjects: 12
Study: 15036822

Group type: EXPERIMENTAL
Intervention: 70% high carbohydrate/15% low fat diet (hc)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 55% standard carbohydrate/30% fat diet (sc)
Number of subjects: 53
Study: 11754630

Group type: EXPERIMENTAL
Intervention: Typherix
Number of subjects: 400

Group type: COMPARATOR
Intervention: Typhim Vi
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Typherix (12 months)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Typhim Vi (12 months)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Typherix (24 months)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Typhim Vi (24 months)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Typherix and Typhim Vi
Number of subjects: 400
Study: 9001137

Group type: EXPERIMENTAL
Intervention: Oral creatine supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurements at the magic angle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numerical spectral simulations
Number of subjects: 0
Study: 8426327

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lignocaine/bupivacaine mixture
Number of subjects: 151
Study: 3303981

Group type: EXPERIMENTAL
Intervention: Hinged cast
Number of subjects: 113

Group type: COMPARATOR
Intervention: Long leg cast
Number of subjects: 113
Study: 30427265

Group type: EXPERIMENTAL
Intervention: Light restriction condition (amber-lens glasses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No-light restriction condition (transparent glasses)
Number of subjects: 15
Study: 28981811

Group type: EXPERIMENTAL
Intervention: Motivation at 6 months
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Social functioning at 6 months
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Work and school participation at 6 months
Number of subjects: 404
Study: 27670928

Group type: EXPERIMENTAL
Intervention: Bonfils™ rigid fibreoptic scope
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SensaScope™ rigid fibreoptic scope
Number of subjects: 200
Study: 24898019

Group type: EXPERIMENTAL
Intervention: Computerized decision support system (CDSS) used in 59% of cases (182/307)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Computerized decision support system (CDSS)
Number of subjects: 912
Study: 23253827

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 141)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Control group (n = 136)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Comparison group (n = 277)
Number of subjects: 649
Study: 19822704

Group type: COMPARATOR
Intervention: Urtoxazumab (0.1 to 3.0 mg/kg in healthy adults; 1.0 and 3.0 mg/kg in pediatric patients)
Number of subjects: 0
Study: 19091934

Group type: EXPERIMENTAL
Intervention: Arabic version of Diabetes-39 (D-39)
Number of subjects: 368
Study: 15155585

Group type: EXPERIMENTAL
Intervention: C + B pamphlet
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: C + B + M pamphlet
Number of subjects: 2700

Group type: COMPARATOR
Intervention: C pamphlet
Number of subjects: 2700
Study: 11377600

Group type: EXPERIMENTAL
Intervention: Class-I below-knee graduated elastic compression stockings
Number of subjects: 231

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 231
Study: 9203805

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 500 micrograms b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched placebo, two puffs b.i.d.
Number of subjects: 20
Study: 7955800

Group type: EXPERIMENTAL
Intervention: Phenytoin (200 mg orally every 8 hours for 11 doses, then 100 mg for 5 doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tirilazad mesylate (1.5 mg/kg as 10-minute intravenous infusions every 6 hours for 21 doses)
Number of subjects: 12
Study: 3118401

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 750 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lithium-ASA combination (ASA 750 mg, trilithium citrate 126 mg, quinine-2 HCl 4.5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29701669

Group type: EXPERIMENTAL
Intervention: Spot urine measurement of DHEAS/serotonin ratio
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Spot urine measurement of serotonin/dopamine ratio
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Spot urine serotonin/dopamine ratio cut-off of >667.38
Number of subjects: 47
Study: 26044403

Group type: EXPERIMENTAL
Intervention: docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab
Number of subjects: 1

Group type: COMPARATOR
Intervention: platinum/5-fluorouracil/cetuximab
Number of subjects: 1
Study: 24035670

Group type: EXPERIMENTAL
Intervention: Nature-based sound therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (headphones with no sound)
Number of subjects: 120
Study: 22113360

Group type: EXPERIMENTAL
Intervention: 17-α-hydroxyprogesterone caproate (17HPC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Corticosteroid (CS)
Number of subjects: 16
Study: 20001563

Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol + 0.25 mg norethisterone acetate
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol + 0.1 mg norethisterone acetate
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 18375890

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha 500 microg with IV iron
Number of subjects: 396

Group type: COMPARATOR
Intervention: Darbepoetin alpha 500 microg without IV iron (standard practice)
Number of subjects: 396
Study: 16332938

Group type: EXPERIMENTAL
Intervention: GHTe (rhGH and Te)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GH (recombinant human GH)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Te (testosterone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12730816

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 102
Study: 10803924

Group type: EXPERIMENTAL
Intervention: TOR20 (20 mg daily)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: TOR40 (40 mg daily)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: TOR60 (60 mg daily)
Number of subjects: 260
Study: 8615961

Group type: EXPERIMENTAL
Intervention: Chemotherapy, Surgery, and Radiotherapy (C/S/XRT)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Chemotherapy and Radiotherapy (C/XRT)
Number of subjects: 314
Study: 1432499

Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine and 0.5% tropicamide
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.5% cyclopentolate and 0.5% tropicamide
Number of subjects: 39

Group type: COMPARATOR
Intervention: NaCl eye drops
Number of subjects: 39
Study: 3975795

Group type: EXPERIMENTAL
Intervention: Autogenous saphenous vein grafts
Number of subjects: 77

Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both graft materials
Number of subjects: 77
Study: 30239007

Group type: EXPERIMENTAL
Intervention: Misogynistic peer norm
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ambiguous peer norm
Number of subjects: 104
Study: 29790073

Group type: EXPERIMENTAL
Intervention: STarT Back risk-stratification strategy
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control clinics (no training)
Number of subjects: 6
Study: 27109453

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5, 10 or 25 mg
Number of subjects: 68
Study: 25011946

Group type: EXPERIMENTAL
Intervention: Exenatide (10-20 µg/day)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Insulin lispro (thrice-daily, titrated to premeal glucose of 5.6-6.0 mmol/L)
Number of subjects: 627
Study: 22394386

Group type: EXPERIMENTAL
Intervention: Proactive care intervention (PRO) including proactive outreach and choice of smoking cessation services (telephone or face-to-face).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC) including access to standard smoking cessation services from VA facility and state telephone quitline.
Number of subjects: 0
Study: 20424250

Group type: EXPERIMENTAL
Intervention: B-vitamin therapy (folic acid 2.5 mg/d, vitamin B(6) 25 mg/d, vitamin B(12) 1 mg/d)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: B-vitamin therapy
Number of subjects: 238
Study: 17414234

Group type: EXPERIMENTAL
Intervention: Olanzapine (14.2 mg/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Haloperidol (7.1 mg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Olanzapine (15.1 mg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Haloperidol (8.5 mg/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Nonfasting glucose levels
Number of subjects: 99
Study: 12920661

Group type: EXPERIMENTAL
Intervention: Insulatard insulin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultratard insulin
Number of subjects: 60
Study: 11887258

Group type: EXPERIMENTAL
Intervention: Two-needle technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: One-needle technique
Number of subjects: 70
Study: 8812025

Group type: EXPERIMENTAL
Intervention: Training in both analytic and synthetic awareness skills (60 children)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-treatment control group (40 children)
Number of subjects: 100
Study: 1474418

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 0
Study: 6141377

Group type: EXPERIMENTAL
Intervention: Nortriptyline treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 34
Study: 30267620

Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/week for 12 weeks)
Number of subjects: 60
Study: 28974291

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Lidocaine injection
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 450
Study: 25911553

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance (n=338)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Observation (n=345)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 683

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance in male patients
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance in female patients
Number of subjects: 683
Study: 23994506

Group type: EXPERIMENTAL
Intervention: Galactose (GAL) CHO drink
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glucose (GLU) CHO drink
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA) drink
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHO ingestion (GAL, GLU, PLA)
Number of subjects: 9
Study: 21875635

Group type: EXPERIMENTAL
Intervention: AS03B-adjuvanted split virion H1N1 vaccine
Number of subjects: 943

Group type: COMPARATOR
Intervention: Non-adjuvanted whole virion H1N1 vaccine
Number of subjects: 943
Study: 18952276

Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement (CEC; Kuraray)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rely X Unicem (RXU; 3M ESPE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calibra (CAL; Dentsply Caulk)
Number of subjects: 18
Study: 16896167

Group type: EXPERIMENTAL
Intervention: Pretraining trial at 45% Vo(2 max) (45UT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pretraining trial at 65% Vo(2 max) (65UT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Posttraining trial at 65% of pretraining Vo(2 peak) (ABT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Posttraining trial at 65% of posttraining Vo(2 peak) (RLT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Leg FFA tracer measured uptake during exercise in RLT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Leg muscle lipid oxidation in ABT
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Muscle FFA fractional extraction during exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Training effect on Vo(2 peak)
Number of subjects: 8
Study: 14748815

Group type: EXPERIMENTAL
Intervention: Caffeine (CYP1A2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tolbutamide (CYP2C9)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Debrisoquine (CYP2D6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorzoxazone (CYP2E1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cocktail of all probe drugs
Number of subjects: 12
Study: 11109306

Group type: EXPERIMENTAL
Intervention: Cocarboxylase (CC) administration, 5 mg/kg body weight, 3 times a week for 12 weeks.
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (mHD, nontreated by CC).
Number of subjects: 35
Study: 8993996

Group type: EXPERIMENTAL
Intervention: P300 amplitude
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P300 latency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear relationship
Number of subjects: 0
Study: 1309691

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (36 mg daily subcutaneous injection)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 204
Study: 6329405

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg oral tablets
Number of subjects: 103

Group type: COMPARATOR
Intervention: Clotrimazole 100 mg vaginal tablets and 1% cream
Number of subjects: 103
Study: 31537233

Group type: EXPERIMENTAL
Intervention: Boiled water
Number of subjects: 900
Study: 28534190

Group type: EXPERIMENTAL
Intervention: Transperitoneal robotic-assisted pyeloplasty
Number of subjects: 80

Group type: COMPARATOR
Intervention: Retroperitoneal robotic-assisted pyeloplasty
Number of subjects: 80
Study: 26898494

Group type: EXPERIMENTAL
Intervention: Microsurgical diskectomy
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Tubular-based endoscopic diskectomy
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Endoscopically assisted microsurgical diskectomy
Number of subjects: 748

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 748
Study: 26056407

Group type: EXPERIMENTAL
Intervention: Patient medication monograph with counseling (PMMC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Patient medication monograph only (PMMO)
Number of subjects: 92
Study: 22525384

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 57
Study: 20518688

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 30
Study: 17825502

Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15969832

Group type: EXPERIMENTAL
Intervention: Safety advertisements showing drinking and dangerous driving resulting in a crash (experimental group)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group watching advertisements showing people choosing not to drive after drinking
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Self/other comparisons used in both studies
Number of subjects: 314
Study: 14575611

Group type: EXPERIMENTAL
Intervention: Detailed informed consent regarding the procedure (group A)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Consent that did not detail specific risks (group B)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Women (before the procedure)
Number of subjects: 125
Study: 10378820

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Diltiazem XR 200 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Diltiazem XR 300 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control (Beta blocker monotherapy)
Number of subjects: 335
Study: 8710157

Group type: EXPERIMENTAL
Intervention: Protein restriction intervention
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (mean blood pressure > 107 mmHg)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Baseline plasma creatinine, proteinuria, and plasma calcium
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Interaction between baseline lying mean blood pressure and proteinuria
Number of subjects: 456
Study: 1944967

Group type: EXPERIMENTAL
Intervention: Clonidine 75 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 31184985

Group type: EXPERIMENTAL
Intervention: Trampoline Training (TT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 26
Study: 28783884

Group type: EXPERIMENTAL
Intervention: Pattern-mixture model approach with multilevel multiple imputation for handling missing data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis using real data from a cluster randomized trial
Number of subjects: 0
Study: 25542910

Group type: EXPERIMENTAL
Intervention: Venner‐PneuX ET tube
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard ET tube
Number of subjects: 240
Study: 23901061

Group type: EXPERIMENTAL
Intervention: m-CIMT + IT (intensive therapy)
Number of subjects: 51

Group type: COMPARATOR
Intervention: m-CIMT
Number of subjects: 51
Study: 21371992

Group type: COMPARATOR
Intervention: Website alone (n = 137)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Website plus human support (n = 133)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Website engagement
Number of subjects: 270
Study: 20635633

Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene supplementation (1.2 mg daily for six months) + Antihelminthic therapy (400 mg albendazole, two doses)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Antihelminthic therapy (400 mg albendazole, two doses)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo for beta-carotene + Antihelminthic therapy (400 mg albendazole, two doses)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo for beta-carotene + Placebo for antihelminthic therapy
Number of subjects: 244
Study: 17959988

Group type: EXPERIMENTAL
Intervention: 26-gauge Atraucan spinal needle (n = 52)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 26-gauge Eldor spinal needle (n = 47)
Number of subjects: 99
Study: 16273805

Group type: EXPERIMENTAL
Intervention: Multi-dimensional health assessment questionnaire (MDHAQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health assessment questionnaire (HAQ) and its derivatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine clinical care without quantitative measures
Number of subjects: 0
Study: 12393355

Group type: EXPERIMENTAL
Intervention: FI(O(2)) 1.0 and end‐tidal sevoflurane 2.0% (Group 100)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FI(O(2)) 0.5 and end‐tidal sevoflurane 1.0% (Group 50)
Number of subjects: 60

Group type: COMPARATOR
Intervention: FI(O(2)) 0.3 and end‐tidal sevoflurane 0.6% (Group 30)
Number of subjects: 60
Study: 10322755

Group type: EXPERIMENTAL
Intervention: Local produced plasma-derived hepatitis B vaccine
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 261
Study: 7707121

Group type: EXPERIMENTAL
Intervention: 400 mg clodronate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 1,600 mg clodronate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 3,200 mg clodronate
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 2757911

Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG) 1-3 g day-1 for 7 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Long-term GVG therapy (2-4 g day-1) for a mean follow-up of 24 months
Number of subjects: 22
Study: 302745

Group type: EXPERIMENTAL
Intervention: Surgical treatment (vein bypass surgery)
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1015
Study: 31326681

Group type: EXPERIMENTAL
Intervention: Complete revascularization (staged PCI of all suitable non-culprit lesions plus optimal medical therapy)
Number of subjects: 4041

Group type: COMPARATOR
Intervention: Culprit lesion-only PCI (optimal medical therapy alone)
Number of subjects: 4041
Study: 28682863

Group type: EXPERIMENTAL
Intervention: Healthy participants with insomnia symptoms
Number of subjects: 54

Group type: COMPARATOR
Intervention: Healthy participants without insomnia symptoms
Number of subjects: 54
Study: 26008801

Group type: EXPERIMENTAL
Intervention: 4 times per week (G4×)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6 times per week (G6×)
Number of subjects: 10
Study: 23239872

Group type: EXPERIMENTAL
Intervention: 2 months of exercise at current recommendations for sedentary men
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 month of reduced physical activity level (PAL) for normal-weight active men
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1 month of bed rest with or without exercise for normal-weight women
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Training (exercise)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Habitual physical activity level (PAL)
Number of subjects: 44
Study: 21783053

Group type: EXPERIMENTAL
Intervention: Healthy Choices intervention
Number of subjects: 142